Formycon to Announce 2025 Financial Results and Participate in Key Investor Conferences
Formycon AG will release its 2025 financial results and provide a 2026 outlook during an April conference call, while planning participation in multiple international investor conferences to showcase its biosimilar pipeline amid growing market opportunities.
Formycon AG plans to publish its financial year 2025 results on April 22, 2026, with management discussing company development, key financial figures, and providing an outlook for the 2026 fiscal year. The conference call will be broadcast live on the internet at 3:00 PM CEST in English, with registration available at https://webcast.meetyoo.de/reg/lNibT8TVWubG. Participants will receive confirmation emails with individual dial-in data, and the presentation and audio broadcast can be accessed via https://www.webcast-eqs.com/formycon-2025-fy. Following a brief presentation, the Management Board will field questions from analysts, with the recorded conference call subsequently available on the Formycon website at https://www.formycon.com/en/investor-relations/publications/.
The company's upcoming financial disclosure comes as biosimilars gain increasing importance in global healthcare markets. By 2032, many biopharmaceutical drugs will lose patent protection, including 45 blockbusters with estimated total annual global turnover exceeding $200 billion. Biosimilars create competition that gives more patients access to biopharmaceutical therapies while reducing costs for healthcare systems. Global biosimilar sales currently amount to approximately $21 billion, with analysts projecting growth to over $74 billion by 2030.
Following the financial results announcement, Formycon management will participate in several international investor conferences during the second quarter of 2026. These events include the Equity Forum Spring Conference in Frankfurt on May 11-12, 2026, featuring CFO Enno Spillner; the publication of first quarter 2026 results on May 28, 2026, with CEO Dr. Stefan Glombitza, CFO Enno Spillner, CBO Nicola Mikulcik, and CSO Dr. Andreas Seidl participating in a conference call and webcast; the Jefferies Global Healthcare Conference in New York City on June 2-4, 2026, with CFO Enno Spillner; the mwb research Roundtable webcast on June 8, 2026, featuring the full executive team; the Annual General Meeting in Munich on June 10, 2026; and the UBS Life Sciences Conference in London on June 18, 2026, with CFO Enno Spillner. Current events can be found at https://www.formycon.com/en/investors/financial-calendar/.
Formycon's participation in these investor conferences highlights the company's position as a leading independent developer of high-quality biosimilars, with two products already on the market and another approved by major regulatory authorities. The company's pipeline includes four candidates in development, including FYB208/dupilumab, covering therapies in ophthalmology, immunology, immuno-oncology and other key disease areas. These investor engagements provide opportunities to communicate Formycon's progress in developing biosimilars that contribute to patient access to effective and affordable medicines while addressing the substantial market opportunity created by upcoming patent expirations of biopharmaceutical blockbusters.